Seyed-Farzad Mohammadi1, Cyrus Alinia2, Maryam Tavakkoli3,4, Alireza Lashay1, Hormoz Chams1,3. 1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran 1336616351, Iran. 2. Department of Public Health, School of Public Health, Urmia University of Medical Sciences, Urmia 5756151818, Iran. 3. Hormoz Chams Research Chair in Public Health Ophthal-mology, Farabi Eye Center of Excellence, Tehran University of Medical Sciences, Tehran 1336616351, Iran. 4. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Abstract
AIM: To compare the lifetime and annual economic burden of spectacles, contact lenses, and refractive surgery in correction of refractive errors. METHODS: This is a cross-sectional study with convenience sampling which 120 patients were interviewed in a tertiary referral hospital in the Iranian health care system. The bottom-up based cost of illness approach was estimated using a face-to-face interview to assess the direct and indirect cost of different refractive errors correction of any correction technologies. RESULTS: Correction with spectacle imposes a total direct cost of US dollar (US$) 342.5 (±8.41) per year and US$9373.5 (±230.1) per lifetime to each patient. These figures for the contact lenses were obtained US$198.3 (±0.12) and US$5203.1 (±256.3) and for refractive surgery were obtained US$19.1 (±1.2) and US$568.1 (±64.6), respectively. Overall, based on age-adjusted prevalence rates, astigmatism had the highest share of refractive errors economic burden with a lifetime direct cost of slightly less than US$5.49 billion, while hyperopia and myopia imposed less than US$5.24 and 4.2 billion on patients, respectively. The annually imposed cost on each individual Iranian patient with refractive errors is US$308.5. CONCLUSION: Based on 18mo post refractive surgery course observation, which is generalized to whole life, refractive surgery significantly imposed much less cost compared with spectacles and contact lenses. Refractive errors among Iranians result in considerable economic burden. Using the refractive surgery instead of other two correction methods has the ability to reduce this economic loss in the future.
AIM: To compare the lifetime and annual economic burden of spectacles, contact lenses, and refractive surgery in correction of refractive errors. METHODS: This is a cross-sectional study with convenience sampling which 120 patients were interviewed in a tertiary referral hospital in the Iranian health care system. The bottom-up based cost of illness approach was estimated using a face-to-face interview to assess the direct and indirect cost of different refractive errors correction of any correction technologies. RESULTS: Correction with spectacle imposes a total direct cost of US dollar (US$) 342.5 (±8.41) per year and US$9373.5 (±230.1) per lifetime to each patient. These figures for the contact lenses were obtained US$198.3 (±0.12) and US$5203.1 (±256.3) and for refractive surgery were obtained US$19.1 (±1.2) and US$568.1 (±64.6), respectively. Overall, based on age-adjusted prevalence rates, astigmatism had the highest share of refractive errors economic burden with a lifetime direct cost of slightly less than US$5.49 billion, while hyperopia and myopia imposed less than US$5.24 and 4.2 billion on patients, respectively. The annually imposed cost on each individual Iranian patient with refractive errors is US$308.5. CONCLUSION: Based on 18mo post refractive surgery course observation, which is generalized to whole life, refractive surgery significantly imposed much less cost compared with spectacles and contact lenses. Refractive errors among Iranians result in considerable economic burden. Using the refractive surgery instead of other two correction methods has the ability to reduce this economic loss in the future.
Authors: John H Kempen; Paul Mitchell; Kristine E Lee; James M Tielsch; Aimee T Broman; Hugh R Taylor; M Kamran Ikram; Nathan G Congdon; Benita J O'Colmain Journal: Arch Ophthalmol Date: 2004-04
Authors: David B Rein; Ping Zhang; Kathleen E Wirth; Paul P Lee; Thomas J Hoerger; Nancy McCall; Ronald Klein; James M Tielsch; Sandeep Vijan; Jinan Saaddine Journal: Arch Ophthalmol Date: 2006-12
Authors: Mehdi Javanbakht; Hamid R Baradaran; Atefeh Mashayekhi; Ali Akbar Haghdoost; Mohammad E Khamseh; Erfan Kharazmi; Aboozar Sadeghi Journal: PLoS One Date: 2011-10-31 Impact factor: 3.240
Authors: Esther Arranz-Marquez; Andreas Katsanos; Vassilios P Kozobolis; Anastasios G P Konstas; Miguel A Teus Journal: Adv Ther Date: 2019-03-11 Impact factor: 3.845
Authors: Li Lian Foo; Carla Lanca; Chee Wai Wong; Daniel Ting; Ecosse Lamoureux; Seang-Mei Saw; Marcus Ang Journal: Front Med (Lausanne) Date: 2021-12-03